AGY — Allergy Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- £369.40m
- £392.24m
- £55.20m
Annual cashflow statement for Allergy Therapeutics, fiscal year end - June 30th, GBP millions except per share, conversion factor applied.
C2020 June 30th | 2021 June 30th | C2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 8.07 | 3.66 | -12.7 | -41.8 | -39.2 |
| Depreciation | |||||
| Non-Cash Items | 0.976 | -0.813 | 0.588 | 1.09 | 3.17 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.476 | 1.42 | -6.1 | 7.57 | -0.456 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 12.5 | 8.4 | -14 | -28.9 | -32.1 |
| Capital Expenditures | -2.55 | -2.56 | -3.06 | -4.67 | -3.4 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.038 | -0.077 | 0.058 | 0.082 | 2.2 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -2.51 | -2.64 | -3 | -4.59 | -1.2 |
| Financing Cash Flow Items | -0.321 | -0.301 | -0.541 | -2.45 | -3.56 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.431 | -2.03 | -2.81 | 27.8 | 31.4 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 9.52 | 3.31 | -19.8 | -5.67 | -1.93 |